CPHI · China Pharma Holdings, Inc.
$0.71
0.00 (-0.14%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$31.13M
Shares
43.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.71
Open$0.72
Day$0.71–0.73
52W close$0.52–8.10
Avg vol 30d653K
Short int196K · 0.5% float · 1.0d
Short vol20%
DataJan 2020–Sep 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$3.91M
Trailing 12 months
Net income (TTM)
−$4.47M
Trailing 12 months
Revenue growth YoY
-7.5%
Year over year
Operating margin
-111.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,156.0%
Year over year · more shares
Price change (1Y)
-64.1%
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−39%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−34%
trailing
6-month return
+13%
trailing
YTD return
−41%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+33% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.46% of float · ▼ -68.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
8 holders — near 3-yr high, broad support
Squeeze score
25
low risk · 0–100
Fundamentals
Revenue growth
−8%
Y/Y
Gross margin
-3%
expanding
EPS growth
+73%
Y/Y
Free cash flow
$88.9K
Balance sheet
$4.3M
net debt
Quant / Vol
risk profile
Volatility
809%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
22.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−39%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+33% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.46% of float · ▼ -68.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
8 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 3%
Range high $8
vs 200-day avg -25%
vs 50-day avg -39%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Anti-Viral/ Infection & Respiratory revenue mix percentage | 33% | three months ended June 30, 2026 filing | — |
| CNS Cerebral & Cardio Vascular revenue mix percentage | 53% | three months ended June 30, 2026 filing | — |
| Cost of revenue as a percentage of total revenue | 91.2% | three months ended June 30, 2026 filing | — |
| Digestive Diseases revenue mix percentage | 13% | three months ended June 30, 2026 filing | — |
| General and administrative expenses as a percentage of total revenue | 145.2% | three months ended June 30, 2026 filing | — |
| Gross profit margin | 8.8% | three months ended June 30, 2026 filing | — |
| Other revenue mix percentage | 1% | three months ended June 30, 2026 filing | — |
| Research and development expenses as a percentage of total revenue | 2% | three months ended June 30, 2026 filing | — |
| Selling expenses as a percentage of total revenue | 12% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CPHI
this stock
China Pharma Holdings, Inc.
|
$31.13M | -41.2% | -8.5% | — | 0.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$59.80B | +22.2% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.49B | +25.6% | +4.3% | 64.0 | 3.2% |
|
GALDY
Galderma Group AG/ADR
|
$44.48B | -8.0% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
8
- % held
- 0.5%
- Net QoQ
- +178.0K sh
- Top holder
- CITADEL ADVISORS LLC
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CPHI | -6.5% | -34.2% | +12.9% | -20.1% | -41.2% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -7.1% | -33.3% | -5.4% | -19.5% | -53.1% |
Key facts
CIK
1106644
CUSIP
16941T401
13F (30d)
1 filings
1 filers